Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | GBT021601, a next generation HbS polymerization inhibitor for the treatment of SCD

Clark Brown • 24 Jun 2022
EHA 2022
Non-Malignant Sickle Cell Disease GBT021601 Voxelotor

Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, outlines the mechanism of action of GBT021601, a next-generation sickle hemoglobin (HbS) polymerization inhibitor developed for the treatment of sickle cell disease (SCD), highlighting the results of Phase I studies evaluating this agent. The study reported that the drug was well-tolerated and led to significantly increased hemoglobin levels. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer

More from Clark Brown

2:20
The evolving treatment landscape of SCD
Clark Brown • 24 Jun 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals